Dapagliflozin promising in providing nephroprotectin in children with CKD, reveals study

A retrospective single-center study published in the American Journal of Nephrology highlighted a potential treatment in pediatric chronic kidney disease (CKD) treatment. The study found promising results of an SGLT2 inhibitor, the dapagliflozin, among the pediatric patients with CKD.

Nephroprotection in pediatric CKD has long been a crucial concern to preserve the residual renal function and enhance the quality of life while delaying the need for renal replacement therapy. The treatment options for pediatric CKD have been predominantly limited to angiotensin-converting-enzyme (ACE) inhibitors and angiotensin-receptor blockers so far. However, recent trials conducted in adults with CKD have suggested that SGLT2 inhibitors might offer significant benefits to pediatric patients. 

The retrospective study by Olil Van Reeth and team assessed the safety profile and potential renal protective effects of dapagliflozin among pediatric CKD patients. The study included 7 patients with an average age of 13.3 years who were already undergoing treatment with ACE inhibitors for identified glomerulopathy that leads to CKD.

During the 15-month observation period, all patients reported dapagliflozin as easy to use. Also, after an initial decline, the slope of estimated glomerular filtration rate (eGFR) stabilization was observed in all patients. The urinary albumin over creatinine ratio displayed a strong tendency to decrease after six months of treatment by indicating potential renal protection. Systolic blood pressure also showed a tendency to decrease after the same duration of treatment. Also, no significant side effects were reported by any of the patients which highlights the tolerability of dapagliflozin in this population.